DURHAM, N.C. -- If youre in public and see someone wearing a mask, that person is doing it for your benefit.
So return the favor.
That was one of several themes to emerge Thursday from a media briefing featuring two Duke medical scholars with vast expertise in vaccines, immunology and the spread of infectious diseases like COVID-19.
Drs. Sallie Permar and Cameron Wolfe took questions for an hour on myriad issues. Here are excerpts:
Dr. Cameron Wolfe, infectious disease specialist
The scientific consensus is actually quite clear. The consensus exists on both the types of masks and their protective efficacy of the individual wearing it, and also the collective benefit for the community.
That second part has really not been emphasized sufficiently. People have sort of viewed a mask as something designed to protect them. While that may be true in a hospital ward in the community the drive is very clearly to protect everyone else.
We understand now very clearly this virus has a pre-symptomatic phase of shedding. Even though I may not be symptomatic today, even though I may have no idea of the fact I may become sick in a day or two I can pass it to other people unwittingly. So my wearing a mask fundamentally protects you when I dont know Im sick or infectious. That part of the science is actually pretty clear.
The wearing of any mask, including cloth masks that folks will now see for sale widely, is very satisfactory at me preventing you getting sick. Thats the public health part of this. When I walk down the street wearing a mask, Im doing that for other folk around me, not fundamentally for me.
Dr. Sallie Permar, pediatric infectious disease specialist
The data has really shown that wearing a mask and preventing those respiratory droplets from spreading on other people is really effective.
The masks are super useful in protecting those that you are around. You wear a mask to prevent infecting others. It does play some role in protecting yourself as well. When we think about requiring masks I think its something that the benefit versus the inconvenience weighs towards the benefit.
Permar
Its hard to remember to wear a mask, and its uncomfortable, so the more you see other people doing it, the more youll be reminded to do it.
I went out and bought some designer masks. I think everyone can show their personality in what masks they choose. The more we require masks, the more it will become normal in our everyday lives.
Wolfe
A lot of it is about good leadership and good example-setting. That is something I wish we could do better on as a community. We have almost politicized mask-wearing. That is some sort of dystopian reality where the wearing of a mask has become something that can be judged.
It comes from political leaders buying into this, it also comes from state and federal politics, with leaders visibly taking this to heart. That has not yet happened, and that needs to change if we want people to buy into this.
Wolfe
Being prepared to put a pause on things should be the first step. Im heartened that our state health departments are finally talking about the implications of what a pause to phase 3 for us would look like. If we consider ourselves to be data-driven and we see the data heading in the wrong way, its nonsense to think we can continue doing the same thing and expect that trajectory to change.
Re-crunching down can still be avoided if you put your efforts into the right mitigation strategies.
If you want to keep opening and if we want to allow businesses to function, an individual choice on behalf of our collective, for me to wear a mask, seems like a smaller move than closing down again.
Permar
School reopening is a really difficult decision that were facing. We will dig into the data that shows that children have a very different course of the infection. They are mostly asymptomatic. Whats really important to understand is how much do they transmit the virus? How much do they transmit virus to their peers? How much do they transmit virus to the staff and teachers? What about when we wear masks? Can we reduce that risk?
What I hope will transpire over the next couple months is the development of child-specific metrics. How many children who are presenting with routine health care test positive? How many children are testing positive in our community? Another example might be absenteeism for influenza-like illness.
What I hope is that the education leaders and the public health leaders can think about schools differently than how we treat bars and restaurants. The appropriate metrics for opening up the community in many places where adults are going to congregate -- the number that are hospitalized, the percent testing positive every day -- I dont know (if) we should apply those same metrics to children and schools.
We know that as much as teachers try and as much as parents try, the virtual learning will not be the same, especially (for) the youngest children who really need the face-to-face interaction.
Wolfe
Many of us, frankly, are starting to see some fatigue in the community. I think that fatigue expands to many things. It extends to mask-wearing, it extends to social-distancing fatigue. Those things have played into disease transmission. Unfortunately, the phased reopening has, I suspect, encouraged a little bit of a letdown of folks guard. You really are seeing that steady march of increasing cases, increasing hospitalizations. Weve got to figure out a way to turn that around.
Permar
I often think about what are going to be the impacts on children now and for the future. They are the ones who will be living with the impacts of this virus the longest.
Its a respiratory virus where children are not often severely affected during the acute infection. However, one thing that has been very new and still developing is seeing this post-infectious syndrome that happens almost exclusively in children. Theres an inflammatory syndrome that can be very severe.
It can land children in the hospital. Were still really understanding what that post-infectious syndrome is. But it has reminded us that children are not completely unaffected by this pandemic.
We know that despite them being a minority of the hospitalizations, they have been impacted majorly when it comes to their development, their education and even their routine health care that has fallen behind in this time.
As we look towards a vaccine, the vaccine is being developed at a most amazing speed. As a vaccinologist, I never thought Id see a vaccine developed within a year. Thats being solely focused on adults, and I think we need to consider adding children to that vaccine development as well. We know children are the targets of most vaccines.
They, of course, are often routes to adults becoming infected as well. Adding children into vaccine development is very important for us to think about now rather than waiting until all adults are vaccinated.
Wolfe
Id be nave not to be concerned. I think it is going to be really incumbent upon public health leaders and federal government leaders to demonstrate a clarity of message here that needs to be uniquely available and visible to the public. Yes, I am worried about skepticism. We have to continue to reiterate active demonstrations of safety.
Permar
If we roll out a vaccine to a large percent of the population and then have a safety concern, that will diminish the faith in vaccines. While were going at this with the most rapid speed because the pandemic is not ending until we have a vaccine, we are also facing the challenge of making sure its the safest vaccine we can put out in a rapid fashion.
Faculty Participants
Dr. Sallie PermarDr. Sallie Permarisa professor of pediatric infectious disease, immunology and molecular genetics atthe Duke School of Medicine. Permar can address how COVID-19 affects mothers and children, how viruses transmit between people and general questions on vaccine development. Read her USA Today op-ed.sallie.permar@duke.edu
Dr. Cameron WolfeDr. Cameron Wolfeis an associate professor of medicine and who can discuss transplant-related infectious diseases, general infectious diseases, biological and emergency preparedness for hospital systems, and influenza and respiratory viral pathogens.cw74@duke.edu
--
Duke experts on a variety of other topics related the coronavirus pandemic can be found here.
More here:
Want to Avoid Another Shutdown? Wear a Mask, Experts Advise - Duke Today
- Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off - R&D World - April 27th, 2025 [April 27th, 2025]
- Dr. Sabine Ehrt Named Chair of the Department of Microbiology and Immunology at Weill Cornell Medicine - WCM Newsroom - April 19th, 2025 [April 19th, 2025]
- RayThera launches with $110 million to advance immunology pipeline - The Pharma Letter - April 10th, 2025 [April 10th, 2025]
- Celebrate Vaccines: The legacy of the tetanus vaccine - British Society for Immunology - April 10th, 2025 [April 10th, 2025]
- Another immunology biotech emerges as Hillstar takes flight with $67M - Endpoints News - March 30th, 2025 [March 30th, 2025]
- Alumnus discovers passion for immunology, teaching at Mercer - Mercer University - March 15th, 2025 [March 15th, 2025]
- The future of immunology - Johnson & Johnson - March 5th, 2025 [March 5th, 2025]
- Immunotherapys Sweet Future: Wrapping up AACR IO 2025 With Glyco-immunology - American Association for Cancer Research (AACR) - March 5th, 2025 [March 5th, 2025]
- J&J receives three CHMP recommendations for immunology and oncology indications - PMLiVE - March 5th, 2025 [March 5th, 2025]
- Greater Austin Allergy, Asthma & Immunology now open in the Shops at the Galleria - Community Impact - March 5th, 2025 [March 5th, 2025]
- As dengue spreads, researchers discover a clue to fighting the virus - La Jolla Institute for Immunology - February 25th, 2025 [February 25th, 2025]
- Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business... - February 25th, 2025 [February 25th, 2025]
- PhD candidate Jesse Lehman receives Kirschstein Award to study immunology - UMass Medical School - February 25th, 2025 [February 25th, 2025]
- Cross-priming in cancer immunology and immunotherapy - Nature.com - February 3rd, 2025 [February 3rd, 2025]
- Sanofi Happy To Spend To Hit Immunology Top Spot - News & Insights - February 3rd, 2025 [February 3rd, 2025]
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]